Drawers that are emptying and others that fill up. The drug shortages, the scourge of patients and health professionals, continue in pharmacies in France. Treatments against psychiatric or mood disorders, which have experienced strong supply tensions since fall, continue to be lacking in many pharmacies, despite a slight better on certain references.
The National Agency for the Safety of Medicines and Health Products (ANSM) notably warned, on August 5, of a “Degradation of availability” Quetiapine -based treatments, an antipsychotic prescribed for 250,000 people in France to treat bipolar disorders and schizophrenia, in 300 mg and 400 mg dosages. The Health Authority believes that supply difficulties will persist until mid-September.
Registered on the list of drugs considered to be essential, Quétiapine, distributed in France under the name of Xeroquel brand as well as under generic versions, already knew in the fall of 2024 strong tensions following production problems in one of its main manufacturers, the Greek shaped Pharmathen, which usually provides 60 % of the French market. The Viatris laboratory, which did not depend on this subcontractor, had so far compensated for these shortcomings. But he too faces it too, difficulty following a “Delay in finished product packaging”.
You have 64.53% of this article to read. The rest is reserved for subscribers.
